Company: APM
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001213900-25-037669
Chunk: 44

Company: Aptorum Group Ltd
Filing Date: 2025-04-30
Form: 20-F
Item: Item 3
Chunk 44
---
 contracted
consultants and advisors to assist us with our operations. As our development and commercialization plans and strategies develop, and
as we have transitioned into operating as a public company, we will need to establish and maintain effective disclosure and financial
controls and make changes in our corporate governance practices. We will need to add a significant number of additional managerial, operational,
sales, marketing, financial and other personnel with the appropriate public company experience and technical knowledge and we may not
successfully recruit and maintain such personnel. Future growth will impose significant added responsibilities on members of management,
including:

  identifying, recruiting, integrating, maintaining and motivating additional employees;                                                                                                                
  managing our internal development efforts effectively, including clinical, the FDA or other comparable regulatory authority review process for our drug and diagnostics technology candidates, wh...  
  improving our operational, financial and management controls, reporting systems and procedures.                                                                                                       

As we refine our operational
strategy to streamline operations, we have adjusted our employment model. The company has shifted from a direct employment approach to
outsourcing key functions, including research and development and back-office operations. While this allows for greater focus and flexibility,
it also introduces dependencies on third-party vendors, which may present new risks related to quality control, data security, and operational
continuity that we are actively managing.

Our future financial performance
and our ability to commercialize our drug candidates will depend, in part, on our ability to effectively manage our future growth, and
our management may also have to divert a disproportionate amount of its attention away from day-to-day activities in order to devote a
substantial amount of time to managing these growth activities.

We currently rely, and for
the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors and consultants for significant
input in selecting and evaluating new products to pursue. These independent organizations, advisors and consultants may not continue to
be available to us on a timely basis when needed, and in such case, we may not have the ability to find qualified replacements. In addition,
if we are unable to effectively manage our outsourced activities, or if the quality or accuracy of the services provided by consultants
is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory
approval of our drug candidates or otherwise advance our business. Furthermore, we may not be able to manage our existing consultants
or find other competent outside contractors and consultants on economically reasonable terms, if at all.

If we are not